Supplementary data.docx

<strong>Supporting Figure 1. Partial DNA sequence of p53R213X gene   harbored in the pLenti-CMV-p53R213X plasmid. </strong>A TGA codon was introduced at the   position of 628-630.
<strong>Supporting Figure 2. Partial cDNA sequence of the p53R213X   gene reversely-transcripted from the H1299p53R213X cells treated   with 200 mM G418 for 72 h. </strong>A TGA codon was   located at the position of 608-610.
<strong>Supporting Figure 3. Partial cDNA sequence of the p53R213X   gene reversely-transcripted from the H1299p53R213X cells treated   with 200 mM Dox (a random   control) for 72 h. </strong>A TGA codon was located at the position of 608-610.
<strong>Supporting Figure 4. Partial cDNA sequence of the p53R213X   gene reversely-transcripted from the H1299p53R213X cells after the   cells were cultured for 72 h (a negative control). </strong>A TGA codon was   located at the position of 609-611.
<strong>Supporting Figure 5. </strong>MTT assay of the viabilities of the H1299 (<strong>a</strong>) and H1299p53R213X cells (<strong>b</strong>) treated with different doses of G418 in combination with 200 mM MMS for 24 h, and n = 3   independent experiments and the data are represented as mean values ± SD.
<strong>Supporting Figure 6. Inducible expression of the FL-p53 and   TR-p53 protein. </strong>Expression levels of FL-p53 and TR-p53 were estimated with western   blotting after the H1299p53R213X cells (right), in comparison with   the H1299 cells (left). β-Actin was used as the loading control, and n=3   independent experiments. (<strong>a</strong>) Cells were   treated with different dose of G418 for 48 h. (<strong>b</strong>) Cells were treated with different dose of G418 in   combination with 200 mM MMS for 24 h.